Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006689
Abstract: Outcomes of older and un fi t adults with acute myeloid leukemia (AML) differ signi fi cantly from their younger counterparts, owing to their adverse disease biology (complex karyotype, antecedent myelo-dysplastic syndrome) and age-related comorbidities.… read more here.
Keywords: double nucleoside; alfa 1200; patients aml; therapy ... See more keywords